
Experience
Touchland to Be Acquired by Church & Dwight
May 15, 2025
Cooley advised Touchland, the fastest-growing brand in the hand sanitizer category in the US, on its acquisition by Church & Dwight (NYSE: CHD) for up to $880 million, including $700 million in cash and Church & Dwight restricted stock at closing, plus a payment of up to $180 million contingent on Touchland’s 2025 net sales.
Related contacts
Related Practices & Industries
Vision Government Solutions Completes Recapitalization With Great Hill Partners
May 6, 2025
Cooley advised Vision Government Solutions, a portfolio company of Rubicon Technology Partners and a leader in the appraisal, computer-assisted mass appraisal and property tax industry, on its majority recapitalization with Great Hill Partners.
Related contacts
Related Practices & Industries
Feedzai Acquires Demyst
April 22, 2025
Cooley advised Feedzai, a global leader in fraud and financial crime prevention, on its acquisition of Demyst, including Demyst’s Zonic data workflow orchestration platform, intellectual property and sophisticated data-integration capabilities.
Related contacts
Cerberus Announces Landmark Investment in Aquatech
April 3, 2025
Cooley advised Cerberus Capital Management, a global leader in alternative investing with approximately $65 billion in assets across complementary credit, real estate and private equity strategies, on its growth investment in Aquatech, a global leader in water technology and services for industrial and infrastructure markets.
Related contacts
Related Practices & Industries
Advanced Instruments Acquires and Merges With Nova Biomedical
March 19, 2025
Cooley advised Advanced Instruments, a subsidiary of Patricia Industries and a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, on intellectual property and licensing aspects in connection with its definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics.